Simmons & Simmons advising Cancer Research UK on healthcare and life sciences collaboration

03 Jul 2019

International law firm Simmons & Simmons is advising Cancer Research UK (CRUK), the world's largest independent funder of cancer research, on a collaboration with SV Health Investors (SV) and related intellectual property access arrangements between Cancer Research Technology, CRUK’s commercialisation subsidiary, with SV.

This high-profile partnership between CRUK, the leading global cancer research charity, and SV, a leading healthcare and life sciences venture capital and growth equity firm, with a track record of creating breakthrough companies and treatments, presents a strong opportunity to progress the charity’s research. It also has the exciting potential to result in scientific breakthroughs.

Simmons & Simmons, working together with CRUK’s capital markets team headed by Anastasia Shiach and CRUK in-house lawyer Andrew Waldron, is advising CRUK on the collaboration and a relationship agreement between its subsidiary, Cancer Research Technology and SV, to give SV access to CRUK funded research and related intellectual property.

The collaboration is intended to make available investment opportunities from among CRUK’s own translational research network. The charity will also collaborate closely with SV to identify promising research from within the CRUK network that could be rapidly developed by securing external investment.

The Simmons & Simmons team was led by partners, Charles Mayo (Corporate) and Matt Pitman (Financial Services), supported by associates Sasha Wagner and George Metcalfe, managing associate Zoe Artanov on tax issues and partner Michael Gavey on IP issues.

Commenting on the firm’s involvement, partner Charles Mayo said: “CRUK’s objective is that, by 2034, 3 in 4 people survive their cancer. This collaboration can help accelerate the transition of research into the clinic for the benefit of cancer patients. We are delighted to be advising CRUK on this important healthcare and life sciences collaboration.”

Andrew Waldron, Head of Legal, Cancer Research Technology, commented on working with Simmons & Simmons: “It’s been a pleasure working with such an expert and engaged team at Simmons & Simmons. Their sector knowledge has been particularly valuable to Cancer Research UK in helping it launch a collaboration which will support the charity’s ambition of seeing 3 in 4 patients survive cancer by 2034”.

This recent work, advising on a collaboration between a leading charity and investment manager, is another example of the firm advising on high-profile collaborations to achieve smarter outcomes. Other examples include the firm’s work advising the Department of Health and Social Care on the formation of the Dementia Discovery Fund, Alzheimer’s Research UK on its participation in the Dementia Research Institute, GlaxoSmithKline on a ground-breaking joint venture investment fund as well as advising the Oil and Gas Climate Initiative on a ten year $1bn collaborative investment fund designed to tackle climate change.

Follow Us 

www.elexica.com 

LinkedIn | Twitter